Comparative effects of different types of mind-body exercise interventions for negative emotions in cancer patients: A systematic review and network meta-analysis.

Complement Ther MedJun 15, 2026 (epub)
Clinical ResearchOncology (Medical)

Xinyu Zhao, Xiangtao Chen, Jian Ma et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the effectiveness of various mind-body exercise interventions on negative emotions in cancer patients, analyzing data from 64 randomized controlled trials involving 4448 participants. The study found that Baduanjin was associated with the greatest reduction in anxiety, while Wuqinxi was most effective for depression, although the certainty of evidence was low to moderate.

Key findings

  • Mind-body exercises significantly reduced anxiety (SMD = -1.14, p < 0.00001) and depression (SMD = -0.87, p < 0.00001) compared to control.
  • Baduanjin ranked highest for anxiety relief, while Wuqinxi was most effective for depression.
  • No serious adverse events were reported in the studies assessing adverse effects.

Why it matters

Understanding the comparative effectiveness of mind-body exercises can help clinicians recommend appropriate interventions to improve emotional well-being in cancer patients, potentially enhancing their quality of life during treatment.

What to keep in mind

The certainty of evidence for network estimates ranged from moderate to very low, primarily due to risk of bias and imprecision.

Source

Published in Complement Ther Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.